ZARONTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zarontin, and when can generic versions of Zarontin launch?
Zarontin is a drug marketed by Parke Davis and Parke-davis and is included in two NDAs.
The generic ingredient in ZARONTIN is ethosuximide. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the ethosuximide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zarontin
A generic version of ZARONTIN was approved as ethosuximide by PHARM ASSOC on November 22nd, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZARONTIN?
- What are the global sales for ZARONTIN?
- What is Average Wholesale Price for ZARONTIN?
Summary for ZARONTIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 94 |
Clinical Trials: | 5 |
Patent Applications: | 3,982 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZARONTIN |
What excipients (inactive ingredients) are in ZARONTIN? | ZARONTIN excipients list |
DailyMed Link: | ZARONTIN at DailyMed |
![ZARONTIN drug patent expirations Drug patent expirations by year for ZARONTIN](/p/graph/s/t/ZARONTIN-patent-expirations.png)
![Drug Prices for ZARONTIN](/p/graph/drug-price/ZARONTIN.png)
Recent Clinical Trials for ZARONTIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Zhejiang University | Early Phase 1 |
Fondation Apicil | Phase 2 |
University Hospital, Clermont-Ferrand | Phase 2 |
Pharmacology for ZARONTIN
Drug Class | Anti-epileptic Agent |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for ZARONTIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parke Davis | ZARONTIN | ethosuximide | CAPSULE;ORAL | 012380-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Parke-davis | ZARONTIN | ethosuximide | SYRUP;ORAL | 080258-001 | Approved Prior to Jan 1, 1982 | AA | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |